[1]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59-61.
　LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(12):59-61.
点击复制

我国上市专利药品可获得性实证研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年12期
页码:
59-61
栏目:
药械管理
出版日期:
2019-11-29

文章信息/Info

Title:
Empirical Study on the Availability of Patented Drugs in China
作者:
李孟林1; 徐 伟1; 杜雯雯1; 陈明艳1; 孟令萱1
1.中国药科大学国际医药商学院，江苏 南京211198
Author(s):
LI Meng-lin; XU Wei; DU Wen-wen; CHEN Ming-yan; MENG Ling-xuan
School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
专利药品; 可获得性; 重大疾病防治用药; 公共卫生用药; 临床急需特效药
Keywords:
patented drug; availability; major disease prevention and treatment drug; public health drugs; clinically needed special drugs
分类号:
R197
文献标志码:
A
摘要:
实证分析我国上市专利药品，特别是其中的重大疾病防治用药、公共卫生用药、临床急需特效药在样本医疗机构中的配备情况及可获得性。整体来看，专利药品在样本医疗机构中的配备品种数呈逐年上升趋势，且占当年我国已上市专利药品比重维持在40%左右；但可获得性较低，仅为5.45%～8.03%，其中，临床急需特效药可获得性最低。对此，需要从研发、使用、医保支付等环节，促进专科药品的研发生产和合理使用。
Abstract:
This paper analyzed the listing of patented drugs in China， especially the availability of major disease prevention and treatment drugs， public health drugs， and clinically needed special drugs in sample medical institutions. On the whole， the number of patented drugs in the sample medical institutions has been increasing year by year， and the proportion of patented drugs in China has remained at around 40%. However， the availability is low， only 5.45% to 8.03%. Among them， the clinically needed special drugs has the lowest availability. In this regard， it is necessary to promote the research and development， production and rational use of specialty medicines from the aspects of research and development， use， and medical insurance payment.

参考文献/References:

[1] 杜雯雯，徐伟，蔡功杰，等.中国儿童用药可及性分析[J]. 中国现代应用药学，2018（1）：128-131.
[2] 易八贤，王广平，霍艳飞，等.基于药物可负担性的罕见病用药定义探讨[J].中国医药工业杂志，2015，46(6):658-664.
[3] 陆承坤，王雨杉，蒋蓉，等.基于注册申请人视角的药品优先审评制度实施情况调查分析[J].中国医药工业杂志，2019(4):450-455.
[4] 徐伟，李孟林.进口医疗器械设“特权”意味着什么[J].中国卫生，2018，393(5):55-56.

相似文献/References:

[1]丁锦希,李梦琦,陈 烨,等.专利药平行进口价格控制效应研究[J].卫生经济研究,2016,(10):8.
[2]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[3]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[4]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
　WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(12):37.
[5]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(12):17.
[6]曹 庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53.
　CAO Zhuang,LI Saisai,CAO Renyuan,et al.Research on the Accessibility of National Medical Insurance Negotiation Drugs ——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities[J].Journal Press of Health Economics Research,2022,39(12):53.
[7]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(12):8.

更新日期/Last Update: 2019-11-29